市場調査レポート
商品コード
1425967
角膜浮腫 - 市場考察、疫学、市場予測(2034年)Corneal Edema- Market Insights, Epidemiology, and Market Forecast-2034 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
角膜浮腫 - 市場考察、疫学、市場予測(2034年) |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 86 Pages
納期: 1~3営業日
|
角膜浮腫の現在の治療法には、根本的な原因や重症度に基づいた専用の戦略が含まれます。初期管理には、炎症を抑え、角膜から余分な液体を取り除くために、高張食塩水や局所ステロイドの使用が含まれることが多いです。経口または外用の炭酸脱水酵素阻害薬などの高浸透圧薬も使用されます。バンデージコンタクトレンズは、角膜表面を滑らかにし、視力を向上させることで症状を緩和することができます。角膜内皮がひどく傷ついている場合は、デスメ膜剥離内皮角膜移植術(DSEK)やデスメ膜内皮角膜移植術(DMEK)などの角膜移植などの外科的介入が考慮されます。選択的レーザー線維柱帯形成術(SLT)のようなレーザー治療は、続発性緑内障を伴う症例に利用できます。さらに、浮腫の原因となる基礎疾患への対処や、潤滑のための人工涙液の使用も包括的な治療計画の一部となりえます。TTHX1114やsirolimusのような治験薬に見られるように、革新的な治療法を模索する継続的な研究により、角膜浮腫を管理する選択肢は将来的に拡大する可能性があります。
角膜浮腫市場は、EO2002、TTHX1114などのような潜在的な薬剤の承認により、プラス成長が予測されます。
当レポートでは、米国の角膜浮腫市場について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。
DelveInsight's "Corneal Edema- Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the corneal edema, historical and forecasted epidemiology and the corneal edema market trends in the United States.
The Corneal Edema market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted United States Corneal Edema market size from 2020 to 2034. The report also covers current Corneal Edema treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2020-2034
Corneal Edema Overview
Corneal edema is characterized by the swelling of the cornea, the transparent, dome-shaped outer layer of the eye that shields the iris and pupil. The cornea is pivotal in directing light onto the retina to facilitate clear vision. The occurrence of corneal edema arises from an excess accumulation of fluid within the cornea, resulting in a blurred or cloudy visual appearance.
Corneal edema can manifest due to diverse factors, each contributing to the accumulation of excessive fluid within the cornea and resulting in a cloudy or hazy visual appearance. One prevalent cause is endothelial dysfunction, characterized by impairment in the cells lining the inner surface of the cornea, known as the endothelium. Conditions like Fuchs' dystrophy or damage from intraocular surgery can compromise the regulatory function of endothelial cells, leading to edema. Trauma or direct injury to the eye can also trigger corneal swelling. Inflammatory conditions, such as uveitis, exacerbate corneal edema by inducing inflammation within the eye.
Corneal edema presents with distinctive symptoms that affect both vision and overall eye comfort. A key symptom is the occurrence of blurred or hazy vision, a consequence of light scattering due to the buildup of fluid in the cornea. Individuals affected by corneal edema often encounter a significant reduction in visual acuity, leading to difficulties in perceiving fine details clearly. Another prevalent symptom is sensitivity to light, referred to as photophobia.
Corneal Edema Diagnosis
The diagnosis of corneal edema involves a comprehensive eye examination conducted by an ophthalmologist. Clinical evaluation typically includes a thorough assessment of the patient's medical history, symptoms, and any relevant contributing factors. Specialized tests, such as corneal topography or pachymetry, may be employed to measure corneal thickness and assess the extent of edema. Slit-lamp biomicroscopy allows for a detailed examination of the cornea, enabling the clinician to observe any signs of swelling, cloudiness, or changes in endothelial cell density. Additionally, visual acuity tests help quantify the impact of corneal edema on the patient's vision.
Corneal Edema Treatment
The treatment of corneal edema is tailored to address its underlying cause. In cases where endothelial dysfunction is a contributing factor, therapies may include hypertonic saline solutions to draw excess fluid from the cornea or the use of hyperosmotic agents for reducing swelling. Lubricating eye drops, often in the form of artificial tears, can provide relief from discomfort and dryness associated with corneal edema. In more severe instances, surgical interventions such as corneal transplantation may be considered to replace damaged tissue.
As the market is derived using the patient-based model, the Corneal Edema epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Etiology-specific Diagnosed Prevalent Cases of Corneal Edema, and Total Diagnosed Prevalent Cases of Corneal Edema covering the United States from 2020 to 2034.
As per DelveInsight's estimations, the total diagnosed prevalent cases of Corneal Edema in the United States were approximately 1,149,967 in 2022 and are projected to increase during the forecast period.
The drug chapter segment of the Corneal Edema report encloses a detailed analysis of corneal edema marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Corneal Edema clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
EO2002: Emmetrope Ophthalmics LLC
EO2002, developed by Emmecell, is a pioneering non-surgical magnetic cell-based therapy designed to modify diseases, particularly addressing corneal edema secondary to corneal endothelial dysfunction. This innovative therapy utilizes the exclusive Magnetic Cell Delivery (MCD) nanoparticle platform, allowing for easier access to treatment before the onset of disability and pain. EO2002 has the potential to prevent or delay the need for more invasive procedures like corneal transplantation. Currently, in Phase I evaluation (EMME-01 study), it aims to assess safety and tolerability in eyes qualifying for full-thickness corneal transplantation or endothelial keratoplasty.
TTHX1114: Trefoil Therapeutics
TTHX1114 is an investigational-engineered variant of the naturally occurring molecule fibroblast growth factor-1 (FGF1), which stimulates corneal endothelial and epithelial cell proliferation and migration as well as protects these cells from stress and injury. Trefoil is conducting clinical trials for TTHX1114 as an intracameral injection in patients susceptible to corneal edema due to endothelial damage, including Fuchs endothelial corneal dystrophy (FECD) and other corneal endothelial dystrophies (CED) and patients with other risk factors undergoing ocular surgeries. The drug is aimed at protecting and regenerating corneal endothelial cells lost due to disease and thereby improving vision.
Note: Detailed emerging therapies assessment will be provided in the final report of Corneal Edema
The current treatment approach for corneal edema involves a tailored strategy based on the underlying cause and severity of the condition. Initial management often includes the use of hypertonic saline solutions and topical steroids to reduce inflammation and draw out excess fluid from the cornea. Hyperosmotic agents, such as oral or topical carbonic anhydrase inhibitors, may also be employed. Bandage contact lenses can provide relief by creating a smoother corneal surface, improving vision. In cases where the corneal endothelium is severely compromised, surgical interventions like corneal transplantation, including Descemet's Stripping Endothelial Keratoplasty (DSEK) or Descemet's Membrane Endothelial Keratoplasty (DMEK), may be considered. Laser procedures, such as Selective Laser Trabeculoplasty (SLT), could be utilized in cases associated with secondary glaucoma. Additionally, addressing the underlying conditions contributing to edema and the use of artificial tears for lubrication may be part of the comprehensive treatment plan. The approach is dynamic, with ongoing research exploring innovative therapies, as seen in investigational drugs like TTHX1114 and sirolimus, potentially expanding the options for managing corneal edema in the future.
The market for Corneal Edema is expected to experience positive growth with the approval of potential drugs like EO2002, TTHX1114 and others.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, EO2002 in the US is expected to be launched by 2028.
Further detailed analysis of emerging therapies drug uptake in the report…
Corneal Edema Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Corneal Edema emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Corneal Edema evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from University of Utah Hospital, the US, Department of Ophthalmology, Columbia University, New York, US, Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, Departments of Cornea and External Diseases, Scripps Clinic Torrey Pines, La Jolla, California and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the US. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or corneal edema market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
Frequently Asked Questions